SCHEMBL2365700

SCHEMBL2365700

COC(=O)c1cccc(Oc2ccc(Cl)cn2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.64
PPARG P37231 3/20 0.52
NR1H2 P55055 1/20 0.50
NR1H3 Q13133 1/20 0.50
MEN1 O00255 1/20 0.48
CASP3 P42574 1/20 0.48
KMT2A Q03164 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
MAPT P10636 2/20 0.47
GAA P10253 1/20 0.47
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
P2RX3 P56373 3/20 0.47
LMNA P02545 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
LIPE Q05469 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13366029 0.86 F10 (0.53) L3MBTL1PPARGNR1H2NR1H3MEN1
SCHEMBL1168418 0.85 PPARG (0.62) PPARGMEN1KMT2AP2RX3NPC1
SCHEMBL693093 0.84 HRH3 (0.59) L3MBTL1MEN1KMT2AMAPK1P2RX3
SCHEMBL19032083 0.84 L3MBTL1 (0.57) L3MBTL1PPARGNR1H2NR1H3MEN1
SCHEMBL3640462 0.84 KDM4E (0.64) L3MBTL1PPARGNR1H2NR1H3MEN1
SCHEMBL20836079 0.83 LMNA (0.65) MEN1CASP3KMT2ASENP8SENP7
SCHEMBL31646829 0.82 L3MBTL1 (0.54) L3MBTL1PPARGMEN1CASP3KMT2A
SCHEMBL10436272 0.81 PPARG (0.48) L3MBTL1PPARGMEN1CASP3KMT2A
SCHEMBL2365744 0.81 LMNA (0.73) L3MBTL1NR1H2MAPTGAAMAPK1
SCHEMBL2365692 0.81 L3MBTL1 (0.56) L3MBTL1PPARGNR1H2NR1H3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927549-B2 Adamantyl benzamide derivatives HIGH POINT PHARMACEUTICALS, LLC (US) 2015-01-06 US disclosed
US-20110224244-A1 Adamantyl Benzamide Derivatives HIGH POINT PHARMACEUTICALS, LLC (US) 2011-09-15 US disclosed
EP-2362730-A1 ADAMANTYL BENZAMIDE COMPOUNDS High Point Pharmaceuticals, LLC (US) 2011-09-07 EP disclosed
WO-2010059618-A1 ADAMANTYL BENZAMIDE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224244-A1 Adamantyl Benzamide Derivatives HSD11B1, HSD17B11, HSD3B1 L3MBTL1 4221/4885PPARG 1286/4885NR1H2 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.